Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE LIBRE DE BRUXELLES is currently navigating 4 pending office actions within the Medical Devices & Mechanical Engineering technology area. These matters are distributed across 4 distinct examiners, showing that each of the 4 actions is being reviewed by a different individual. This distribution means that prosecution outcomes are dependent on 4 individual examiner perspectives rather than a point of contact with 1 examiner. The portfolio spans 3 distinct art units, which reflects the technical diversity within its primary technology area.
CASSANDRA SENN GRIZER is the busiest examiner for the company, though this individual is only managing 1 pending office action. This indicates that the workload is spread across the examiner pool, with no single examiner dominating the current prosecution landscape. With 4 pending office actions and 4 distinct examiners, the company must manage multiple simultaneous legal and technical arguments. The involvement of 3 distinct art units further suggests that while the technology is centered on Medical Devices & Mechanical Engineering, the specific applications fall under different examination guidelines. This variety requires a strategy to address the requirements of each examiner and art unit involved. The company's success depends on navigating these 4 distinct examiner relationships effectively.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 75.0% | +18.8% |
| CATINA, MICHAEL ANTHONY | 1 | 31.5% | +30.3% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| RAGHU, GANAPATHIRAM | 1 | 73.6% | +26.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 23d |
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 84d |
| 18710727 | COVID-19 THERANOSTIC | GRIZER, CASSANDRA SENN | — |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 23d |
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 84d |
| 18710727 | COVID-19 THERANOSTIC | GRIZER, CASSANDRA SENN | — |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | — |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| 1759 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710727 | COVID-19 THERANOSTIC | GRIZER, CASSANDRA SENN | — | §101§103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 3791 | §103§112Other | Non-Final OA | 84d | Pending | Apr 03, 2024 |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Non-Final OA | 23d | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial